DA‐7503, a novel tau aggregation inhibitor, ameliorates tau pathology and reduces CSF tau in transgenic mouse models of Alzheimer’s disease and primary tauopathies

Documenti analoghi

• Pharmacological characterization of DA‐7503: a novel tau aggregation inhibitor in clinical development for Alzheimer’s disease and primary tauopathies
  di: Min Jung Lee, et al.
  Pubblicazione: (2025)
• HDAC inhibition and acetylation‐driven disulfide‐linked aggregation of TDP43: implications for TDP43 proteinopathies
  di: Sungsu Lim, et al.
  Pubblicazione: (2025)
• Identification of CSF and brain tau species in Alzheimer's Disease that are highly correlated with tau pathology
  di: Julie Lee, et al.
  Pubblicazione: (2025)
• A small‐molecule microtubule‐stabilizing agent safely reduces Aβ plaque and tau pathology in transgenic mouse models of Alzheimer's disease
  di: Yuemang Yao, et al.
  Pubblicazione: (2024)
• Sepsis‐induced systemic inflammation and tau pathology examined in the PS19 transgenic mouse model
  di: Quan Vo, et al.
  Pubblicazione: (2025)